Replies to post #313441 on MATRIX Penny Stocks

[OCKHAM'S RAZOR]

MCET nHOD @ .002 23M vol 10 DAY AVG 19M


MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.
http://www.multicelltech.com/investor-information/Investor-Relations-and-Stock-Information